Stockreport

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Rallybio Corporation  (RLYB) 
PDF – RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy –– RLYB116 Confirmatory PK/PD Study to I [Read more]